BIO-key International (NASDAQ:BKYI) Releases Earnings Results, Misses Expectations By $0.12 EPS

BIO-key International (NASDAQ:BKYI) posted its earnings results on Tuesday. The technology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.12), FiscalAI reports. The business had revenue of $1.24 million for the quarter, compared to analyst estimates of $2.20 million. BIO-key International had a negative return on equity of 73.33% and a negative net margin of 70.23%.

BIO-key International Trading Up 4.3%

Shares of BKYI stock opened at $0.60 on Tuesday. BIO-key International has a 1 year low of $0.51 and a 1 year high of $1.97. The firm has a market capitalization of $6.49 million, a PE ratio of -0.58 and a beta of 0.41. The stock has a fifty day moving average of $0.63 and a two-hundred day moving average of $0.70. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.13 and a current ratio of 1.26.

Institutional Investors Weigh In On BIO-key International

A hedge fund recently raised its stake in BIO-key International stock. Geode Capital Management LLC increased its position in BIO-key International Inc. (NASDAQ:BKYI) by 49.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 48,892 shares of the technology company’s stock after purchasing an additional 16,271 shares during the period. Geode Capital Management LLC owned about 0.45% of BIO-key International worth $26,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 26.51% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on BKYI shares. Wall Street Zen raised shares of BIO-key International to a “sell” rating in a research note on Saturday, January 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of BIO-key International in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

BIO-key International Company Profile

BIO-key International, Inc is a developer and provider of fingerprint biometric identity and access management solutions, serving enterprise and government customers. The company’s core offerings include a range of fingerprint readers and authentication software designed to verify user identity across physical and digital environments. By leveraging proprietary template-on-card and template-on-device technologies, BIO-key seeks to enhance security and streamline user access without reliance on traditional passwords.

In addition to hardware sensors, BIO-key delivers software platforms that integrate with existing IT infrastructures such as Microsoft Active Directory and major workforce management systems.